Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
AssigneeTillotts Pharma AG
InventorsThomas Buser, Emilio P. Camporesi
Life of this patent
Estimating the term…
Abstract
Inflammatory bowel disease, especially Crohn's disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases the acid in the ileum. Preferably the oral dosage form is a gelatine capsule coated with a poly(ethylacrylate-methylmethacrylate).
Claims17
An oral dosage form for treating inflammatory bowel disease, containing an active compound selected from the group consisting of omega-3 polyunsaturated acids and pharmaceutically acceptable salts thereof and containing a neutral polyacrylate coating which is resistant to release of the active compound for a period of 30 to 60 minutes at pH 5.5 whereby the active compound is released in the ileum.
An oral dosage form comprising a coated capsule containing as an active principle an omega-3 polyunsaturated acid in free acid form or a pharmaceutically acceptable salt thereof, wherein the coating is a neutral polyacrylate whereby the active principle is released in the small intestine.
An oral dosage form comprising a capsule containing eicosapenta-5,8,11,14,17-enoic acid, docosahexa-4,7,10,13,16,19-enoic acid or a mixture thereof, and coated with poly(ethylacrylate-methylmethacrylate).
Dependencies are inferred from the claim text.